As more private companies begin to explore or restart IPO processes after a prolonged period of market uncertainty, observers are optimistic about an increase in IPO activity moving into the first half of 2024. Life sciences companies face unique considerations when exploring a possible IPO, and the structuring of an effective strategy and story is key for a successful public listing.
Join Fenwick Partners Amanda Rose and Michael Pilo for a conversation with Goldman Sachs Managing Director Lyla Bibi on current U.S. IPO market conditions and what they mean for life sciences companies exploring a public listing. Learn about key preparation strategies and what to focus on now to be ready to IPO in the next window.
This webinar will be recorded and is eligible for CLE credit.